Polycystic ovary syndrome (PCOS) affects an estimated 8 to 13 percent of women of reproductive age, making it one of the most common endocrine disorders in women worldwide. Inositol — specifically the combination of myo-inositol and d-chiro-inositol — has emerged as one of the most rigorously studied nutritional interventions for PCOS, with a growing body of randomized controlled trials supporting its effects on insulin sensitivity, hormone levels, ovulation, and menstrual regularity.
Quick Facts
| Topic | Key Point |
|---|---|
| Most studied form for PCOS | Myo-inositol (MYO) alone or MYO + D-chiro-inositol (DCI) |
| Standard protocol | 4,000 mg myo-inositol + 100 mg d-chiro-inositol daily (40:1 ratio) |
| Primary mechanism | Insulin sensitization; restoration of inositol signaling |
| Key outcomes | Improved ovulation, lower androgens, better menstrual regularity |
| Time to effect | 12-16 weeks for hormonal and menstrual changes; 8-12 weeks for insulin markers |
| Safety | Well tolerated; mild GI side effects at high doses; no known serious adverse effects |
What Is Inositol?
Inositol is a carbocyclic sugar that exists in nine isomeric forms, of which myo-inositol and d-chiro-inositol are the most physiologically relevant. Despite sometimes being called vitamin B8, inositol is not a vitamin — it is synthesized by the body and obtained from food, particularly fruits, beans, grains, and nuts.
In cellular biology, inositol serves as a second messenger in insulin signaling pathways. When insulin binds its receptor, inositol phosphoglycans (IPGs) containing myo-inositol and d-chiro-inositol are released and act as intracellular mediators of insulin action. This makes inositol availability directly relevant to insulin sensitivity.
PCOS and Insulin Resistance
Insulin resistance is present in approximately 50-70% of women with PCOS and is considered central to its pathophysiology. Even lean women with PCOS often show insulin signaling abnormalities. Elevated insulin stimulates the ovaries to produce excess androgens (testosterone, androstenedione) and impairs follicle maturation — contributing to the hallmark features of PCOS: irregular cycles, hyperandrogenism, and polycystic ovarian morphology.
Research shows that women with PCOS have an altered ratio of myo-inositol to d-chiro-inositol in their follicular fluid and blood. Specifically, there is excess d-chiro-inositol and a deficit of myo-inositol in ovarian tissue. This imbalance impairs follicle development and oocyte quality. The enzyme that converts myo-inositol to d-chiro-inositol (epimerase) is stimulated by insulin, so hyperinsulinemia drives excessive local conversion, depleting the myo-inositol that follicles need.
The 40:1 Ratio: Why It Matters
The physiological plasma ratio of myo-inositol to d-chiro-inositol in healthy women is approximately 40:1. This ratio is not arbitrary — it reflects the proportion needed to support both systemic insulin signaling (requiring MYO) and local tissue signaling (requiring DCI) optimally.
Research has tested multiple ratios and dosing protocols. The 40:1 MYO:DCI combination — typically 4,000 mg MYO and 100 mg DCI daily — consistently performs well across outcomes including:
- Ovulation rate
- Menstrual cycle regularity
- Testosterone and androgen levels
- Fasting insulin and HOMA-IR (insulin resistance index)
- LH/FSH ratio normalization
High-dose DCI alone or at very high ratios has shown concerns in some research. One study found that a very high DCI protocol (400:1 DCI-heavy ratio) impaired oocyte quality in PCOS patients undergoing IVF, potentially by driving the same myo-inositol depletion in ovarian tissue that the disease itself causes. This supports the position that the 40:1 ratio is preferable to high-DCI protocols for most women.
Key Clinical Studies
Unfer et al., 2017 — Systematic Review Unfer and colleagues conducted a comprehensive systematic review of randomized controlled trials evaluating inositol in women with PCOS. Across 13 RCTs, myo-inositol alone or in combination with d-chiro-inositol improved metabolic parameters (insulin, HOMA-IR, triglycerides), hormonal profiles (testosterone, LH/FSH ratio), and clinical outcomes including ovulation and menstrual regularity. The reviewers concluded that inositol — particularly MYO — represents a viable, well-tolerated intervention for PCOS management.
Nordio and Proietti, 2012 This randomized trial compared MYO+DCI at the 40:1 ratio against MYO alone in overweight PCOS women over six months. Women receiving the combined formula showed greater improvements in BMI, FSH levels, insulin resistance, and androgen markers. The study helped establish the 40:1 combined ratio as a benchmark protocol.
Colazingari et al., 2013 — Oocyte Quality Women with PCOS undergoing IVF showed improved oocyte and embryo quality when supplemented with myo-inositol compared to DCI, supporting the ovary’s specific need for MYO for follicular function.
Meta-analysis evidence confirms that inositol supplementation lasting at least 24 weeks significantly decreases fasting insulin, reduces the HOMA index, increases SHBG (sex hormone binding globulin — which reduces free testosterone), and improves ovulation frequency.
Effects on Hormones
Testosterone and androgens: Multiple studies show 25-40% reductions in free testosterone and total testosterone in women using MYO-based protocols. Lower androgens reduce hirsutism, acne, and male-pattern hair concerns associated with PCOS.
LH/FSH ratio: An elevated LH/FSH ratio is common in PCOS and disrupts normal ovulation. Inositol supplementation normalizes this ratio in multiple trials, supporting follicle maturation and ovulation.
SHBG: Inositol increases SHBG, a protein that binds free testosterone and reduces its bioavailability. Higher SHBG effectively lowers the androgenic burden on tissues even without directly reducing total testosterone production.
AMH: Anti-Mullerian hormone is elevated in most PCOS patients and reflects the large pool of small follicles. Some studies show modest AMH reduction with inositol, suggesting a normalization of follicular dynamics.
Effects on Ovulation and Fertility
Ovulation restoration is one of the most clinically meaningful outcomes of inositol supplementation.
In women with PCOS who are not ovulating regularly (oligo-ovulation or anovulation), myo-inositol supplementation restores spontaneous ovulation in a significant proportion within 12-16 weeks. Reported rates vary across trials, but studies consistently show 40-60% of previously anovulatory women resuming ovulation on MYO protocols.
For women pursuing fertility treatment, inositol supplementation before ovarian stimulation has been shown to improve the quality of oocytes retrieved and reduce the amount of gonadotropin required to achieve follicle maturation — a meaningful clinical and economic benefit.
Standard Dosing Protocol
The most commonly studied and recommended protocol for PCOS is:
Myo-inositol: 4,000 mg/day (2,000 mg twice daily, typically with meals) D-chiro-inositol: 100 mg/day (50 mg twice daily)
This delivers the 40:1 ratio in a divided dose format that mirrors physiological patterns and minimizes GI side effects.
For women using myo-inositol alone (without DCI), the standard dose is 4,000 mg/day. Evidence supports this dose for insulin and hormonal improvements, though the combined formula shows stronger effects in head-to-head comparisons.
Allow 8-12 weeks minimum before assessing metabolic changes, and 12-16 weeks for menstrual and ovulatory effects. Many women continue supplementation for 6-12 months or indefinitely if well tolerated.
Side Effects
Inositol is well tolerated at therapeutic doses. The most common side effects are gastrointestinal: nausea, mild bloating, or loose stool, particularly when starting or at higher doses. Dividing the dose (twice daily with food) reduces GI symptoms significantly.
No serious adverse events have been attributed to inositol supplementation in clinical trials. It does not appear to interact with common PCOS medications, though women taking metformin, oral contraceptives, or fertility medications should inform their physician before adding inositol.
Inositol vs Metformin
Metformin is the most commonly prescribed insulin-sensitizing medication for PCOS. Several studies have directly compared inositol (particularly MYO) to metformin:
- Hormonal improvements are generally comparable
- Ovulation rates are similar between groups
- Inositol has a substantially better GI tolerability profile than metformin
- Inositol is available without a prescription
These comparisons do not imply that inositol should replace metformin for women who benefit from pharmaceutical management — particularly those with significant insulin resistance or metabolic syndrome. However, inositol represents a legitimate first-line option for women with milder presentations or those who prefer a non-pharmaceutical approach.
Who Is Inositol Best For?
Inositol is most likely to produce meaningful results for women with:
- Confirmed PCOS with oligovulation or anovulation
- Elevated fasting insulin or HOMA-IR
- Elevated androgens (testosterone, DHEA-S)
- Irregular or absent menstrual cycles
- Interest in improving fertility without or alongside medical intervention
Women with PCOS who ovulate regularly and have normal insulin sensitivity may see less dramatic effects, though improvements in oocyte quality and hormone markers are still plausible.
References
- Unfer V, Carlomagno G, et al. (2017) — Effects of inositol(s) in women with PCOS: a systematic review of randomized controlled trials. Int J Endocrinol Metab.
- Nordio M, Proietti E. (2012) — The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. PMID: 23360696
- Colazingari S, et al. (2013) — The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes. PMID: 23430870
- Unfer V, et al. (2014) — Hyperinsulinemia alters myoinositol to d-chiroinositol ratio in the follicular fluid of patients with PCOS. PMID: 24462163
Shop WHYZ
- WHYZ Myo-Inositol — pure myo-inositol powder, unflavored, no fillers. Available at WHYZ.com.